Lexicon Pharmaceuticals LXRX Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's total liabilities & equity?
- Lexicon Pharmaceuticals (LXRX) reported total liabilities & equity of $268.82M in Q1 2026.
- How has Lexicon Pharmaceuticals's total liabilities & equity changed year-over-year?
- Lexicon Pharmaceuticals's total liabilities & equity decreased by 9.7% year-over-year, from $297.67M to $268.82M.
- What is the long-term trend for Lexicon Pharmaceuticals's total liabilities & equity?
- Over 5 years (2020 to 2025), Lexicon Pharmaceuticals's total liabilities & equity has grown at a -1.9% compound annual growth rate (CAGR), from $203.79M to $184.99M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.